Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Dec 12, 2016 4:58pm
129 Views
Post# 25588397

RE:RE:RE:RE:RE:RE:RE:ASTRAZENECA CUTTING U.S.JOBS/ PATENT EXPIRATIONS/ 208 MIGHT

RE:RE:RE:RE:RE:RE:RE:ASTRAZENECA CUTTING U.S.JOBS/ PATENT EXPIRATIONS/ 208 MIGHT
This is the patent you are referring to. It is for co-treatment with RVX-208 and rosuvastatin.

COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION

https://www.freepatentsonline.com/y2016/0206617.html

Go to that website above and scroll down a bit and you can get the pdf (or try clicking here).

Pretty cool actually. I don't think I ever saw them break down the MACE numbers by type of statin and HDL level. If nothing else, just scroll through and look at the images.
Abstract:
The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through co-administration of therapeutically effective amounts of RVX-208 or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof. The invention further provides compositions comprising a therapeutically effective amount of RVX-208 or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of rosuvastatin or a pharmaceutically acceptable salt thereof.

Bullboard Posts